This inventor holds 1 USPTO granted patent. Top assignee: Astra Zeneca U.k. Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Jason Grant Kettle: Innovator in Selective Inhibitors
Introduction
Jason Grant Kettle is a notable inventor recognized for his contributions to the field of pharmaceuticals. He is particularly known for his work on JAK1 selective inhibitors, which have significant implications in treating various diseases. With a focus on innovation, Kettle has made strides in developing effective therapeutic solutions.
Latest Patents
Kettle holds 1 patent related to his research on JAK1 selective inhibitors. This patent represents a critical advancement in the understanding and treatment of conditions that involve the JAK1 pathway.
Career Highlights
Kettle is currently employed at AstraZeneca U.K. Limited, a leading global biopharmaceutical company. His role at AstraZeneca allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.
Collaborations
Throughout his career, Kettle has worked alongside esteemed colleagues such as Karl Magnus Nilsson and Annika Birgitta Margareta Åstrand. These collaborations have fostered an environment of innovation and have led to significant advancements in their shared field of expertise.
Conclusion
Jason Grant Kettle's work in the development of JAK1 selective inhibitors showcases his commitment to advancing medical science. His contributions at AstraZeneca U.K. Limited and collaborations with other professionals highlight the importance of teamwork in achieving innovative breakthroughs.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile